Most cases of EBV+ DLBCL exhibit activation of nuclear factor‐κB and Janus kinase‐signal transducer and activator of transcription‐related gene (JAK/STAT) pathways and usually have an activated/non‐germinal center B‐cell immunophenotype (ABC/non‐GCB).10, 11, 12 Most of our cases (90%) of EBV+ iDLBCL had non‐GCB immunophenotype, which may be related to their adverse outcome. Here, SOAT1 is linked to diffuse large B-cell lymphoma.